Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial with MEAI-based CMND-100 in patients diagnosed with Alcohol Use Disorder (AUD). 

The active ingredient in proprietary CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcohol while producing a euphoric alcohol-like experience. 

See also: Next-Generation Psychedelics: The Case Of MEAI …

Full story available on